MSI-H Tumors
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor (NCT03607890) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2018-11-16 |
Track MSI-H Tumors automatically
Every clearance here is in the API, with alerts when new ones post.